OPTIMIZING THE USE OF RISK FACTORS TO GUIDE THE COST-EFFECTIVE USE OF PALIVIZUMAB PROPHYLAXIS AGAINST SEVERE RESPIRATORY SYNCYTIAL VIRUS INFECTION IN KOREAN INFANTS BORN 32-35 WEEKS' GESTATIONAL AGE

被引：0

作者：

Keary, I ^{[1
]}

Kang, J. M. ^{[2
]}

Paes, B. ^{[3
]}

Rodgers-Gray, B.

Fullarton, J. ^{[1
]}

Tarride, J. E.

Yang, H. J. ^{[4
]}

Chang, Y. S. ^{[5
]}

Carbonell-Estrany, X. ^{[6
]}

机构：

[1] Violicom Med Ltd, Reading, Berks, England

[2] Yonsei Univ, Severance Childrens Hosp, Coll Med, Seoul, Gyeonggi, South Korea

[3] McMaster Univ, Hamilton, ON, Canada

[4] Soonchunhyang Univ Seoul Hosp, Seoul, Gyeonggi, South Korea

[5] Sungkyunkwan Univ, Samsung Med Ctr, Sch Med, Seoul, Gyeonggi, South Korea

[6] Hosp Clin Barcelona, Barcelona, Spain

来源：

关键词：

D O I：

暂无

中图分类号：

F [经济];

学科分类号：

02 ;

摘要：

EE390

引用

页码：S125 / S125

页数：1